Westlake Valuation

Is 0LVK undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 0LVK when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 0LVK ($130.58) is trading below our estimate of fair value ($227.68)

Significantly Below Fair Value: 0LVK is trading below fair value by more than 20%.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for 0LVK?

Key metric: As 0LVK is barely profitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for 0LVK. This is calculated by dividing 0LVK's market cap by their current revenue.
What is 0LVK's PS Ratio?
PS Ratio1.4x
SalesUS$12.13b
Market CapUS$16.79b

Price to Sales Ratio vs Peers

How does 0LVK's PS Ratio compare to its peers?

The above table shows the PS ratio for 0LVK vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average2.2x
ESNT Essentra
1.4x1.8%UK£430.4m
ZTF Zotefoams
1.3x6.6%UK£167.7m
CRDA Croda International
3x5.1%UK£4.9b
ANTO Antofagasta
3.2x8.8%UK£16.4b
0LVK Westlake
1.4x5.9%US$16.8b

Price-To-Sales vs Peers: 0LVK is good value based on its Price-To-Sales Ratio (1.4x) compared to the peer average (2.2x).


Price to Sales Ratio vs Industry

How does 0LVK's PS Ratio compare vs other companies in the GB Chemicals Industry?

6 CompaniesPrice / SalesEstimated GrowthMarket Cap
JMAT Johnson Matthey
0.2x-43.3%US$3.23b
SYNT Synthomer
0.1x5.0%US$336.13m
CAR Carclo
0.2x7.0%US$29.99m
HEIQ HeiQ
0.2xn/aUS$9.61m
0LVK 1.4xIndustry Avg. 1.2xNo. of Companies6PS01.22.43.64.86+
6 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: 0LVK is expensive based on its Price-To-Sales Ratio (1.4x) compared to the UK Chemicals industry average (1.2x).


Price to Sales Ratio vs Fair Ratio

What is 0LVK's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

0LVK PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio1.4x
Fair PS Ratio1.1x

Price-To-Sales vs Fair Ratio: 0LVK is expensive based on its Price-To-Sales Ratio (1.4x) compared to the estimated Fair Price-To-Sales Ratio (1.1x).


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 0LVK forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$130.58
US$156.13
+19.6%
6.1%US$175.00US$135.00n/a15
Nov ’25US$132.50
US$164.44
+24.1%
7.7%US$185.00US$135.00n/a16
Oct ’25US$149.43
US$163.19
+9.2%
8.5%US$185.00US$135.00n/a16
Sep ’25US$145.01
US$161.62
+11.5%
8.7%US$185.00US$135.00n/a17
Aug ’25US$145.73
US$159.10
+9.2%
9.7%US$185.00US$123.00n/a16
Jul ’25US$143.10
US$160.98
+12.5%
9.8%US$185.00US$123.00n/a16
Jun ’25US$158.58
US$159.98
+0.9%
9.9%US$185.00US$123.00n/a16
May ’25US$152.70
US$154.04
+0.9%
10.8%US$185.00US$123.00n/a17
Apr ’25US$152.77
US$144.21
-5.6%
9.9%US$185.00US$123.00n/a17
Mar ’25US$138.35
US$142.98
+3.3%
9.8%US$185.00US$123.00n/a16
Feb ’25US$139.46
US$141.94
+1.8%
9.5%US$185.00US$123.00n/a16
Jan ’25US$139.91
US$137.94
-1.4%
10.2%US$175.00US$108.00n/a16
Dec ’24US$129.32
US$134.00
+3.6%
11.8%US$175.00US$108.00n/a15
Nov ’24US$115.09
US$134.67
+17.0%
11.9%US$175.00US$108.00US$132.5015
Oct ’24US$124.30
US$136.56
+9.9%
11.9%US$175.00US$108.00US$149.4316
Sep ’24US$132.62
US$137.29
+3.5%
11.7%US$175.00US$108.00US$145.0117
Aug ’24US$137.10
US$127.35
-7.1%
8.0%US$150.00US$108.00US$145.7317
Jul ’24US$119.41
US$124.78
+4.5%
8.2%US$138.00US$106.00US$143.1018
Jun ’24US$105.49
US$126.41
+19.8%
8.5%US$144.00US$107.00US$158.5817
May ’24US$111.36
US$123.75
+11.1%
7.9%US$140.00US$107.00US$152.7016
Apr ’24n/a
US$123.06
0%
8.3%US$142.00US$103.00US$152.7716
Mar ’24US$118.03
US$119.76
+1.5%
10.3%US$142.00US$100.00US$138.3517
Feb ’24US$122.31
US$113.41
-7.3%
10.7%US$138.00US$94.00US$139.4617
Jan ’24US$102.10
US$110.18
+7.9%
11.4%US$138.00US$85.00US$139.9117
Dec ’23US$108.23
US$106.29
-1.8%
13.3%US$138.00US$80.00US$129.3217
Nov ’23US$98.54
US$106.29
+7.9%
15.4%US$138.00US$79.00US$115.0917

Analyst Forecast: Target price is less than 20% higher than the current share price.


Discover undervalued companies